Zacks.com on MSN7d
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...
GlobalData on MSN7d
GSK’s depemokimab shows promise in Phase III trials for chronic rhinosinusitis
Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.
FierceBiotech8d
GSK's depemokimab reduces polyps in phase 3 trials, adding weight to upcoming filing
GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...
pharmaphorum8d
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...
Daily9d
Twice-Yearly Depemokimab Effectively Lowers Exacerbation Rates in Severe Eosinophilic Asthma: Study Reveals
The findings reveal that administering Depemokimab twice yearly significantly lowers the annualized rate of asthma ...
Pharmabiz7d
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...
London South East8d
Positive results of ANCHOR trials of depemokimab
Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks · Depemokimab is an ultra-long-acting ...